On May 15, 2024, Seelos Therapeutics, Inc. filed a Certificate of Change with the Nevada Secretary of State to execute a 1-for-8 reverse stock split and reduce the total authorized shares from 400 million to 50 million. The reverse stock split, effective as of 12:01 a.m. Eastern Time on May 16, 2024, will combine every eight shares of existing common stock into one share, maintaining the same par value. This move aims to meet Nasdaq's minimum bid price requirement for continued listing. Post-split, the common stock will trade under the same ticker 'SEEL' with a new CUSIP number. The reverse stock split will also affect outstanding warrants and stock options, with adjustments to exercise prices, and reduce the number of shares available under the company's equity incentive plans. The common stock began trading on a split-adjusted basis on May 16, 2024.

On May 15, 2024, Seelos Therapeutics, Inc. filed a Certificate of Change with the Nevada Secretary of State to execute a 1-for-8 reverse stock split and reduce the total authorized shares from 400 million to 50 million. The reverse stock split, effective as of 12:01 a.m. Eastern Time on May 16, 2024, will combine every eight shares of existing common stock into one share, maintaining the same par value. This move aims to meet Nasdaq's minimum bid price requirement for continued listing. Post-split, the common stock will trade under the same ticker 'SEEL' with a new CUSIP number. The reverse stock split will also affect outstanding warrants and stock options, with adjustments to exercise prices, and reduce the number of shares available under the company's equity incentive plans. The common stock began trading on a split-adjusted basis on May 16, 2024.